Abstracts tagged "bone disease"

Abstract Number: 2706 • 2015 ACR/ARHP Annual Meeting
3D Location of Erosions in an Early Rheumatoid Arthritis Population: An MRI Study Using Statistical Shape Models with Implications for Pathogenesis
Michael A. Bowes¹, Gwenael Guillard¹, Z. Xie², Bethanie Wilkinson² and Philip G. Conaghan³, ¹Imorphics, Manchester, United Kingdom, ²Pfizer Inc, Groton, CT, ³University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom
Background/Purpose: Concepts of erosion pathogenesis in rheumatoid arthritis (RA) have been based on radiographs, although MR images are much better able to visualise erosions. Statistical…
Abstract Number: 2796 • 2014 ACR/ARHP Annual Meeting
A Novel Mouse Model of Osteochondromagenesis By Deleting NFATc1 in Mesenchymal Progenitors and Postnatal Chondrocytes
Xian-Peng Ge¹, Susan Y. Ritter², Julia F. Charles³, Kelly Tsang² and Antonios O. Aliprantis², ¹Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Osteochondromas are the most common benign bone tumor and are characterized by cartilage-capped bony projections from the external surface of bone. These lesions may…
Abstract Number: 228 • 2014 ACR/ARHP Annual Meeting
Is Adult Hypophosphatasia a Cardiovascular Risk Factor?
Leyre Riancho-Zarrabeitia¹, Maria T. García-Unzueta², Alfonso Corrales³, Juan Gómez-Gerique² and José A. Riancho⁴, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁴Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. University of Cantabria, Santander, Spain
Background/Purpose Mild forms of adult hypophosphatasia may have subtle manifestations, and may go unrecognized. The aim of this study was to get a better knowledge of its clinical spectrum. Methods We performed a computerized search of low total alkaline phosphatase among laboratory records. The diagnosis of hypophosphatasia was confirmed by measuring serum pyridoxal phosphate (PLP) and bone alkaline phosphatase. Carotid ultrasonography was performed in patients and controls with a MyLab 70…
Abstract Number: 397 • 2013 ACR/ARHP Annual Meeting
Does Elevated Disease Activity Or Medication Use Influence The Bone Density Of The Prepubertal Offspring In Pregnant Women With Rheumatoid Arthritis?
Florentien D.O. de Steenwinkel¹, Anita C.S. Hokken-Koelega², Johanna Hazes³ and Radboud J.E.M. Dolhain¹, ¹Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ²Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands, ³Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Elevated rheumatoid arthritis disease activity and prednisone use during pregnancy are both associated with a lower bone mineral density (BMD) of the patients, but…
Abstract Number: 1965 • 2012 ACR/ARHP Annual Meeting
Adenosine Regulates Bone Metabolism Via A₁, A_2A and A_2B Receptors in Bone Marrow Cells From Normal and Patients with Multiple Myeloma
Wenjie He¹, Amitabha Mazumder² and Bruce N. Cronstein³, ¹Dept of Med, Div of Rheum, NYU, New York, NY, ²NYU Cancer Center, New York, NY, ³Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Multiple myeloma is a haematologic malignancy that is characterized by osteolytic bone lesions, wherein coupled bone remodeling is disrupted with increased osteoclast activation and…
Abstract Number: 1035 • 2012 ACR/ARHP Annual Meeting
Characterisation of New Bone Formation in Gout: A Quantitative Site-by-Site Analysis Using Plain Radiography and Computed Tomography
Nicola Dalbeth¹, Aaron Milligan², Barnaby Clark², Fiona M. McQueen³ and Anthony Doyle⁴, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Radiology, Auckland District Health Board, Auckland, New Zealand, ³Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: Radiographic descriptions of gout have noted the tendency to hypertrophic bone changes. The aim of this study was to characterise the features of…
Abstract Number: 32 • 2012 ACR/ARHP Annual Meeting
Development of a Quantitative Model of Endotoxin-Induced Calvarial Bone Erosion Utilizing Micro-Computed Tomography and Pax-It Imaging Analysis Software
Diane Thome, Donald Souza, Aruna Behera, Jie Zheng, Jennifer Swantek and Gerald H. Nabozny, Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: To facilitate an understanding of the biological factors involved in inflammation- mediated bone loss, in vitro systems and murine models of bone loss, such…
Abstract Number: 33 • 2012 ACR/ARHP Annual Meeting
Novel Targets for Blocking Osteoclast-Mediated Resorption in Inflammatory Disorders
Kevin P. McHugh¹, Tania N. Crotti¹, Jun Li², Jon Hill³, Gerald H. Nabozny², Steven R. Goldring⁴ and P. Edward Purdue⁵, ¹Orthopedic Surgery, Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Boston, MA, ²Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ³Scientific Knowledge Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, ⁴Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medical Center, New York, NY
Background/Purpose: Osteoclasts are specialized myeloid lineage cells that mediate both pathologic and physiologic bone remodeling Fully differentiated and functional osteoclasts are found exclusively associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].